Company: DVAX
Filing Date: 2025-04-07
Form Type: PREC14A
Source: 0001193125-25-074629
Chunk: 13

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-07
Form: PREC14A
Chunk 13
---
eca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in
May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery
and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate
finance from California State University at Fullerton and is a certified public accountant (inactive).

As a chief financial officer in
the pharmaceutical industry for over 10 years, Mr. Farrow has an understanding of financial reporting, budgeting, forecasting and financial analysis and how these are carried out in the healthcare industry. He also has a deep understanding of
the regulatory environment in the pharmaceutical industry and knowledge of the drug development process. Mr. Farrow’s significant financial background, including as a chief financial officer in the healthcare industry, would bring to the
Company substantial financial expertise and an experienced perspective to the Board on issues relating to finance.

Michael Mullette, age 45.

Michael Mullette is an experienced drug development and commercialization professional with decades of experience growing
businesses. Mr. Mullette has most recently been serving as interim CEO of Lykos Therapeutics since September 2024 and Chief Operating Officer since March of 2022. Before that, Mr. Mullette served as vice president of North America
commercial operations for Moderna from July 2020 to March 2022, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the
COVID-19 pandemic. Before Moderna he spent almost 20 years with Sanofi Pasteur working in vaccine, commercial, business development, operations, strategy, planning, marketing and sales in roles of increasing
levels of responsibility in the US, France, Australia, Japan, and Canada. Mike earned his Bachelor of Business Administration from Villanova University and an M.B.A. from Lehigh University.

As an interim chief executive officer, chief operating officer, and executive in the healthcare industry, Mr. Mullette provides insight
into operational matters, along with industry